Belatacept Post Depletional Repopulation to Facilitate Tolerance
NCT00565773 is a phase 2 interventional trial sponsored by Allan D Kirk, MD, PhD. As of 21 Nov 2026, it is completed. It studies Alemtuzumab, Belatacept and Sirolimus in Organ Transplantation. The registry lists an enrollment of 40 participants at 2 sites in 1 country. The registry lists a start date of 31 Dec 2007 and a primary completion date of 1 Jul 2017.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00565773 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Allan D Kirk, MD, PhD |
| Enrollment | 40 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Organ Transplantation |
| Drugs | Alemtuzumab, Belatacept and Sirolimus |
| Start | 31 Dec 2007 |
| Primary completion | 1 Jul 2017 |
| Study completion | 1 Jul 2017 |
| Last update posted | 11 Feb 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Antonio Guasch, MD
Emory University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University Hospital
Atlanta
- the Emory Clinic
Atlanta
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00565773
Each answer restates registry values shown on this page.
What is NCT00565773?
NCT00565773 is a phase 2 interventional trial sponsored by Allan D Kirk, MD, PhD. It studies Alemtuzumab, Belatacept and Sirolimus in Organ Transplantation.
Who leads NCT00565773?
The registry names Antonio Guasch, MD (principal investigator, Emory University) as the overall official.
Where does NCT00565773 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00565773 study?
The registered drug and biological interventions are Alemtuzumab, Belatacept and Sirolimus.
When did NCT00565773 end?
The registry lists a primary completion date of 1 Jul 2017 and a study completion date of 1 Jul 2017. The sponsor last updated the record on 11 Feb 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.